133 related articles for article (PubMed ID: 2311021)
1. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ; Nortier JW; Thijssen JH
Acta Endocrinol (Copenh); 1986 Aug; 112(4):487-93. PubMed ID: 3751462
[TBL] [Abstract][Full Text] [Related]
3. Primary treatment of macroprolactinomas with Parlodel LAR.
van 't Verlaat JW; Lancranjan I; Hendriks MJ; Croughs RJ
Acta Endocrinol (Copenh); 1988 Sep; 119(1):51-5. PubMed ID: 3414319
[TBL] [Abstract][Full Text] [Related]
4. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
van't Verlaat JW; Croughs RJ; Brownell J
Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
van 't Verlaat JW; Croughs RJ
Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
7. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
9. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies.
Ahmed M; al-Dossary E; Woodhouse NJ
Fertil Steril; 1992 Sep; 58(3):492-7. PubMed ID: 1521641
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
12. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
13. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
14. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.
Mbanya JC; Mendelow AD; Crawford PJ; Hall K; Dewar JH; Kendall-Taylor P
Br J Neurosurg; 1993; 7(5):519-27. PubMed ID: 8267889
[TBL] [Abstract][Full Text] [Related]
15. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the therapeutic results of bromocriptine treatment of prolactin microadenoma and macroadenoma].
Jin ZM; Shi YF; Chen GL
Zhonghua Nei Ke Za Zhi; 1990 Nov; 29(11):669-72, 702-3. PubMed ID: 2086009
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]